Optimal anticoagulation duration of unfractionated and low molecular weight heparin in non-ST elevation acute coronary syndrome: A systematic review of the literature

摘要: Abstract Introduction In this PCI era, non-invasive management for patients presenting with non-ST elevation acute coronary syndrome continues to be relevant in several clinical circumstances. The duration of anticoagulation non-invasively treated group is not clear. use heparin can associated fatal side effects. Thus, defining the optimal therapy has significant implications patient safety and cost. Methods Literature search was conducted using Medline (PubMed Ovid SP), Embase, Cochrane Central Register Controlled Clinical Trials (CENTRAL) Database Systematic Review (CDSR) from inception these databases till present (August 2013). Only studies on humans English language were included. We included only published trials which used UFH or LMWH as agent. Results Initial revealed 548 182 meeting inclusion criteria full review. reported 20 an average treatment 2–8days. There a trend towards increased bleeding without improvement cardiovascular outcomes when continued more than 5–7days. No single trial directly analyzed composite end point outcome adverse events correlation anticoagulation. Conclusion lack good quality evidence define NSTE ACS. Well-designed, methodologically rigorous database are required determine shortest achieves benefits anticoagulants while minimizing costs risks prolonged anticoagulant